Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Ambrisentan

Ambrisentan

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Ambrisentan

20 trials tracked of Ambrisentan: 11 in phase 3 or 4 and 2 with published results. The most-cited published study has 105 citations.

20Trials tracked
11Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 5 Phase 3 6 Phase 2 5 Phase 1 1 Other / NA 3
  1. Phase 4 Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan Completed · 105 cited
  2. Phase 3 Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial Completed · 49 cited
  3. Phase 4 Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension Completed
  4. Phase 4 The Effects of Ambrisentan on Exercise Capacity in Fontan Patients Completed
  5. Phase 4 An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH) Completed
  6. Phase 4 Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1) Completed
Show 14 more trials
  1. Phase 3 Study of Ambrisentan in Participants With Pulmonary Hypertension Completed
  2. Phase 3 A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202) Completed
  3. Phase 3 Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH) Completed
  4. Phase 3 A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) Completed
  5. Phase 3 Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension Completed
  6. Phase 2 Ambrisentan in Single Ventricle Completed
  7. Phase 2 Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension Completed
  8. Phase 2 Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529 Completed
  9. Phase 2 Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) Completed
  10. Phase 2 Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension Completed
  11. Phase 1 The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers Completed
  12. N/A Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet Completed
  13. N/A Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis Completed
  14. N/A A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma). Completed

Showing the 20 most-cited and recently-updated of 20 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.